


Kivin Jacobsen¹, PhD; Dagmar Walter²; Michael Stubbington²; Katherine Pfeiffer²; Charlotte Halgreen¹; Stephane Boutet²; Liselotte Brix¹
¹Immudex, Copenhagen, Denmark, ²10x Genomics, CA, US

1) Introduction:

Identification of disease-specific T-cell epitopes is key to the development of many novel vaccines and immunotherapies. Profiling disease-specific T cells, emerging during a cellular immune response e.g. in tumor development or destruction, is an important aspect of personalized immunotherapy.

We have developed dCODE™ Dexramer® technology, for detection of antigen specific T-cells through DNA barcode using next generation sequencing. In combination with 10x Genomics feature Barcode protocol the technology allows coupling of TCR-specificity and –sequence of antigen-specific T cells (ASTC), in combination with transcriptional analysis.

Here we show data from sample analysis with a panel of 50 MHC dCODE™ Dexramer® specificities, including 6 negative controls, spanning 8 alleles.



2) dCODE™ Dexramer® panel design and staining

CD8-enriched HPBMC from a healthy donor (HLA-Alleles: A*0201, A*1101, B*3501) were stained with a panel of 50 dCODE Dexramer reagents according to established protocol. The panel consisted of 44 dCODE™ Dexramer®, comprising different viral and cancer epitopes, and 4 negative control dCODE™ Dexramer® reagents (Table 1). Cells were phenotyped using 11 TotalSeq™C antibodies (BioLegend); CD3, CD19, CD45Ra, CD4, CD8a, CD14, CD45Ro, CD279(PD-1), CD127(IL7Ra), CD197(CCR7), HLA-DR.

The stained sample was FACSsorted for CD8+ MHC dCODE™ Dexramer®+ cells and loaded onto a 10x Chromium controller. Using the Chromium single cell V(D)J Reagent kit with feature barcoding technology, 3 libraries were generated: Feature barcode (dCODE and TotalSeq), VDJ and RNA expression libraries. Next generation Sequencing (NGS) of each library were performed using Illumina sequencing platform.

| Cat.no | Allele | Peptide | Antigen | Cat.no | Allele | Peptide | Antigen |
|-------------|--------|------------|-------------------|-------------------|----------|-------------|----------------|
| WA2131-PfBC | A*0101 | VTEHDTLLY | CMV/Viral | WB2177-PfBC | A*0201 | RMFPNAPYL | WT-1/Cancer |
| WB2660-PfBC | A*0201 | KTWGOYVQV | gp100/Cancer | WB2191-PfBC | A*0201 | YLNLDHLEPWI | BCL-X/Cancer |
| WB2162-PfBC | A*0201 | ELAGIGILTV | MART-1/Cancer | WB2652-PfBC | A*0201 | MLDLQPETT | HPV/Viral |
| WB3697-PfBC | A*0201 | CLLWSFQISA | Tyrosinase/Cancer | WC2197-PfBC | A*0301 | ILGGALQAK | IE-1/CMV |
| WB2158-PfBC | A*0201 | IMDQVPPFSV | gp100/Cancer | WC2656-PfBC | A*0301 | RLRAEAQVK | EBV/Viral |
| WB3247-PfBC | A*0201 | SLLMWITQV | NY-ESO-1/Cancer | WC2632-PfBC | A*0301 | RIAAWMAATY | BCL-2L1/Cancer |
| WB3497-PfBC | A*0201 | KVAELVHFL | MAGE A3/Cancer | WD2175-PfBC | A*1101 | IVTDFSVIK | EBV/Viral |
| WB3474-PfBC | A*0201 | KVLEVIKIV | MAGE-A1/Cancer | WD2149-PfBC | A*1101 | AVFDRKSDAK | EBV/Viral |
| WB5066-PfBC | A*0201 | CLLGTYTQDV | Kana. B dioxyg. | B*3501 | IPSNVHHY | CMV/Viral | |
| WB2143-PfBC | A*0201 | LLDFVRFMGV | EBV/Viral | WF2196-PfBC | A*2402 | AVAQKFKI | CMV/Viral |
| WB3307-PfBC | A*0201 | LLMGLTGVV | HPV/Viral | WF2133-PfBC | A*2402 | QYDPVAALF | CMV/Viral |
| WB2144-PfBC | A*0201 | CLLGLTMTV | EBV/Viral | WH2165-PfBC | B*0702 | QPRAPRIRP | EBV/Viral |
| WB3531-PfBC | A*0201 | YLLEMLWRL | EBV/Viral | WH2136-PfBC | B*0702 | TPRYTGGGAM | CMV/Viral |
| WB3529-PfBC | A*0201 | FLVALILL | EBV/Viral | WH2166-PfBC | B*0702 | RPPIFRRL | EBV/Viral |
| WB2161-PfBC | A*0201 | GILGFVFTL | Flu/Viral | WH2135-PfBC | B*0702 | RPHERNGTIVL | EBV/Viral |
| WB2130-PfBC | A*0201 | GLCTLVAML | EBV/Viral | WI2148-PfBC | B*0801 | RAKFKOLL | EBV/Viral |
| WB2132-PfBC | A*0201 | NLVPMTAVT | CMV/Viral | WI2137-PfBC | B*0801 | ELRRKMMYIM | CMV/Viral |
| WB2139-PfBC | A*0201 | ILKEPVHGV | HIV/Viral | WI2147-PfBC | B*0801 | FLRGRAYGL | EBV/Viral |
| WB5335-PfBC | A*0201 | FLASKIGRLV | P-lipase | Negative controls | | | |
| WF2639-PfBC | A*2402 | CYTWNQMINL | WT1/Cancer | | | | |
| WB2646-PfBC | A*0201 | RTLNAWVKV | HIV/Viral | WA3580-PfBC | A*0101 | SLEGGIGLY | NC |
| WB2157-PfBC | A*0201 | KLQCVLHV | PSA/Cancer | WA3579-PfBC | A*0101 | STEGGLAY | NC |
| WB2141-PfBC | A*0201 | LLFGYPTVY | HTLV-1/Viral | WB2666-PfBC | A*0201 | ALUAPVHAV | NC |
| WB3338-PfBC | A*0201 | SLFNTVATL | HIV/Viral | WF3231-PfBC | A*2402 | AVSSAGASI | NC |
| WB3339-PfBC | A*0201 | SLYNTVATLY | HIV/Viral | WH3397-PfBC | B*0702 | GPAESAAGL | NC |
| WB3340-PfBC | A*0201 | SLFNTVATLY | HIV/Viral | NI3233-PfBC | NR | AAKGRGAAL | NC |

3) NGS Data analysis:


Analysis of the sequencing data were performed using Cell Ranger, by dimensional reduction, clustering, and t-SNE calculation. Loupe Cell Browser, and Loupe V(D)J Browser were used for visual analysis (10x Genomics software package).

Analysis method:

The following stringent rules were set up for the targeted analysis:

- The “background” threshold was defined using the negative controls
- The dCODE positive ASTC populations were defined as having a signal over the said threshold “signals” defined by the negative control reagents
- Only MHC matching the alleles of the donor were considered positive
- ASTC’s must be CD8+
- ASTC’s binding more than one dCODE Dexramer was excluded


Fig. 1: Setting dCODE Dexramer threshold



(Fig 1, left A-F.) Staining observed for the 6 negative control dCODE Dexramer reagents. (Fig 1, T=1 to T=4), shows the effect of increasing the threshold on the negative control. The $Threshold = \log_2[reads+1] = 4$ was used to analyze each of the 44 dCODE Dexramer specificities, in the assay. Same approach was used for the Antibody staining, using iso type control antibodies.

5) Clonal distribution of ASTC’s

| Table 2: | Cat.no. | WB2161 | WD2175 | WD2149 | WB2162 |
|---------------------------------|---------|--------|--------|--------|--------|
| Specificity (pMHC) | | FLU | EBV1 | EBV2 | MART 1 |
| Number of positive cells | | 2594 | 4472 | 1846 | 187 |
| Number of specific clones | | 732 | 389 | 166 | 180 |
| No. cell in highest freq. clone | | 110 | 2373 | 1241 | 8* |
| Frequency of highest clone | | 4% | 53% | 67% | 4% |
| Clones of > 1 cell | | 251 | 44 | 19 | 1 |
| Clones of 1 cell | | 481 | 345 | 147 | 179 |
| Frequency of Clones with 1 cell | | 66% | 89% | 89% | 99% |
| Frequency of Clones > 1 cell | | 34% | 11% | 11% | 1%* |




The distribution of unique TCR clones were evaluated for each of the 4 positive antigens.

- The influenza epitope (Flu), detected a high number of different TCR clones. This may reflect that influenza is a reoccurring infection where some TCR clones falls away in between the infective periods, and new clones are generated at next infection, resulting in a high diversity of expanded clones.
- The two EBV epitopes is quite alike and detected fewer and larger TCR clones. This may reflect, that EBV is a persistent infection, where TCR clones are selected over time, decreasing the clonal distribution, and increasing the number of same clones.
- The MART1 epitope detected low number of TCR clones with a high distribution. Only one clonal TCR with more than 1 cell was observed, the rest was single different clonotypes. This may reflect, that MART 1 is an endogenous cancer antigen, which is unexpressed in healthy donors..

4) Antigen-specific T-cell populations detected

Each of the 44 MHC dCODE reagent data were analyzed for identification of positive cells using a threshold=4 and visualized by t-SNE plot


- WB2161 A*0201/GILGFVFTL (Flu MP, Influenza)
- WD2175 A*1101/IVTDFSVIK (EBNA 3B, EBV)
- WD2149 A*1101/AVFDRKSDAK (EBNA 3B, EBV)
- WB2162 A*0201/ELAGIGILTV (MART-1)



- 4 distinct dCODE Dexramer positive ASTC populations were found (Fig 2). Each population was bisected, indicating different phenotypes within each ASTC populations (see why in 6)

6) Phenotyping the bisected ASTC populations:

The found ASTC populations were further phenotyped using TotalSeq™C antibody data. Two markers, HLADR, and CCR7 (Fig 3), was shown to stain one of each of the bisected ASTC clusters.



HLADR and CCR7, both have increased labeling on the same half of each of the dCODE positive populations, indicating that the bisecting of the ASTC populations in the t-SNE plots was driven by these two activations makers, HLADR and CCR7 (Fig 3).

Conclusion

High plex staining using MHC dCODE™ Dexramer®, in combination with TotalSeq™C antibodies (BioLegend), in the 10x Chromium 5’ feature barcoding workflow gives a powerful tool for deep phenotyping of immune relevant cells.

- ✓ We identified four different antigen specific T cell populations, in a CD8 sorted HPBMC samples, using a dCODE Dexramer panel of 44 specificities.
- ✓ Paired clonal TCR sequence and TCR specificity (MHC dCODE Dexramer positive) were directly obtained, and quantified, by overlaying the VDJ expression of each cell with the dCODE Positive cell clusters
- ✓ The antigen specific T cell populations were further phenotyped using TotalSeq™C antibody data, identifying HLADR and CCR7 subpopulations within each of the ASTC clusters
- ✓ This targeted analysis method revealed immunological answers, however, is restrained by the t-SNE cluster analysis. Cells that does not cluster well in t-SNE space, such as cells of low frequency, or dCODE positive cells with very diverse TCR’s, might be overseen.
- ✓ In waste dataset the information is merely unlimited. To get relevant biological information filtered out, both unbiased bioinformatics and “targeted” analysis (drilling though deep phenotyping) will be important.

